AI-Powered antibiotic stewardship: ReAct Asia Pacific’s consultation

2025-03-26

ReAct Asia Pacific, recently convened a consultation meeting at Ananthapuri Hospital, Trivandrum, India, to assess Dr. Antibot, an AI-driven WhatsApp chatbot developed by Dure Technologies with the support of ReAct Africa. This digital tool is designed to support antibiotic stewardship initiatives by providing real-time, evidence-based guidance to healthcare providers (HCPs) and patients, contributing to efforts against antimicrobial resistance.

The chatbot Dr. Antibot

The chatbot Dr. Antibot integrates recommendations from the World Health Organization’s AWARE Antibiotic Book to offer guidance on antibiotic use. The chatbot, accessible in English and Malayalam via WhatsApp, requires minimal onboarding through QR codes, making it particularly suitable for resource-limited settings.

Key features include:

• Clinical decision support: Instant access to WHO guidelines for healthcare professionals.
• Patient education and support: Medication reminders, educational materials, and adherence surveys.
• Multilingual accessibility: Designed to accommodate local linguistic preferences in Kerala, India.

Strengths and potential impact

Participants at the consultation praised the chatbot’s user-friendly design, scalability, and potential to enhance awareness and stewardship efforts to address antibiotic resistance.

By decentralizing access to standardized antibiotic guidelines, Dr. Antibot could significantly improve clinical decision-making and patient engagement in diverse healthcare settings.

Challenges and areas for improvement

A key concern raised during the discussion was the chatbot’s exclusive reliance on WHO guidelines, which may not fully address complex clinical scenarios or regional antibiotic resistance patterns. To enhance its applicability, stakeholders recommended:

• Integration of local guidelines: Incorporating hospital-specific protocols and regional antibiotic resistance data.
• Enhanced diagnostic capabilities: Expanding AI-driven functionalities to address nuanced clinical queries.

Refine Dr. Antibot

To refine Dr. Antibot, ReAct Asia Pacific is invited the attendees to:

• Participate in pilot-testing within clinical and community settings.
• Contribute region-specific treatment protocols.
• Provide iterative feedback for continuous improvement.

Importance of digital innovation and collaboration

The consultation meeting underscored the importance of digital innovations like Dr. Antibot in enhancing antibiotic stewardship. While challenges remain, ongoing collaboration between healthcare providers, researchers, and policymakers will be crucial in refining the tool’s capabilities. Importantly, Dr. Antibot is designed to complement, not replace, clinical expertise. By integrating localized treatment protocols and improving AI-driven responses, the chatbot aims to support healthcare providers in making informed decisions while ensuring alignment with best practices.

Strengten antibiotic stewardship at scale

Dr. Salman, ReAct Africa, also shared valuable perspectives on how AI-driven tools like Dr. Antibot can strengthen antibiotic stewardship at scale.